Professor Patrick Harter is a faculty member at the Institute of Neuropathology, Ludwig Maximilian University of Munich (LMU), where he leads research in neuro-oncology and molecular diagnostics of CNS tumors. His work focuses on glioblastoma, meningioma, and brain metastasis, with emphasis on epigenetic mechanisms like DNA methylation and metabolic adaptations in the tumor microenvironment. Research interests span: Molecular classification of brain tumors using DNA methylation profiling Therapeutic targeting of BRAF/MEK and PI3K/Akt/mTOR pathways Role of hypoxia and metabolic plasticity in treatment resistance Liquid biopsy development for non-invasive tumor monitoring His recent publications demonstrate a strong trend toward integrating epigenetic, metabolic, and immunotherapeutic approaches. Articles frequently explore: Novel biomarkers for tumor grading and prognosis Mechanisms of therapy resistance in gliomas Impact of tumor microenvironment on metastasis
Professor Udo Oppermann serves as Professor of Molecular Biology and Director of Laboratory Sciences at the Institute of Musculoskeletal Sciences, Botnar Research Centre, University of Oxford. He is also Deputy Director of the Oxford Centre of Translational Myeloma Research and a fellow at St Catherine's College. His educational background includes a Diploma in Human Biology (1990) and PhD in Pharmacology and Toxicology (1994), both earned with distinctions from Philipps University Marburg. Prior academic appointments include Associate Professor at Karolinska Institutet (until 2004) and sabbatical work at Yale University. Research focuses on epigenetic mechanisms in disease through drug and target discovery using systems biology and single-cell approaches . Key disease targets include metabolic disorders, inflammatory conditions, and malignant diseases—particularly multiple myeloma and secondary bone cancers. His group pioneers chemical biology applications in primary tumor microenvironments. Current funding sources include Cancer Research UK, Innovate UK, EPSRC, Royal Society-Newton Fund, Bristol Myers Squibb, Bayer Healthcare, GlaxoSmithKline, Blood Cancer UK, and Leducq Foundation. Notable research trends show increasing emphasis on epigenetic regulation in immune cells (2020-2024), single-cell technologies for myeloma (2022-2024), and translational applications of chromatin modifiers (2016-2019). Recent work integrates metabolomics with epigenetic mechanisms in gynecological and hematological disorders. He supervises doctoral research including Singh K.'s 2024 thesis on sonodynamic therapy mechanisms. Leadership roles encompass directing Oxford's Molecular Laboratory Sciences division and co-leading translational myeloma research initiatives.
Jing Fan is an Associate Professor of Medical Microbiology & Immunology at the University of Wisconsin-Madison and a metabolism investigator at the Morgridge Institute for Research. She serves as a faculty trainer in multiple graduate programs, including Cellular and Molecular Biology (CMB) and the Integrated Program in Biochemistry (IPiB). Education: PhD, 2014, Princeton University Her research focuses on metabolic reprogramming in immune and cancer cells, particularly macrophages and neutrophils during immune responses and tumor microenvironment interactions. She employs metabolomics, lipidomics, and fluxomics integrated with biochemical and genetic techniques. The 15 most recent publications highlight her lab's work on metabolic flexibility in neutrophils and macrophages nutrient utilization during immune activation epigenetic regulation by metabolic pathways metabolic interactions in tumor microenvironments systems-level metabolic flux analysis translational applications for immunotherapy . She leads the Fan Lab, which includes current team members such as graduate students Carlos Mellado Fritz, Nick Arp, and Jorgo Lika, alongside postdoctoral fellows James Votava and Julia Nunes. Alumni include PhD graduates Emily Britt (Thermo Fisher Scientific) and Gretchen Seim (Genentech), as well as MD/PhD graduate Laura Steenberge (University of Pittsburgh Residency).
Stelios Andreadis is the SUNY Distinguished Professor of Chemical and Biological Engineering at the University at Buffalo, affiliated with the School of Engineering and Applied Sciences. He directs the Cell, Gene and Tissue Engineering Center and previously led the Stem Cells in Regenerative Medicine (SCiRM) Training Program. His research focuses on stem cell bioengineering, vascular and gland tissue engineering, and biomaterials design. He holds a PhD in Chemical Engineering from the University of Michigan and has been funded by NIH, NSF, and NYSTEM, totaling over $20M. His awards include the NSF CAREER Award, SUNY Chancellor’s Excellence in Scholarship, and AIMBE and BMES Fellowships. Research interests span stem cell rejuvenation, cell-free vascular grafts, and metabolic reprogramming. He has published 140+ papers and advised 28 PhD students, many now in academia or industry. His lab co-founded Angiograft, LLC to commercialize vascular grafts. Key achievements include developing self-healing vascular grafts and demonstrating monocyte recruitment for vascular regeneration. His work bridges basic science and clinical applications in regenerative medicine.
Andrea H. Brand serves as the Frederick L. Ehrman Professor of Cell Biology and Professor of Neuroscience at NYU Grossman School of Medicine, New York University, where she chairs the Department of Cell Biology. Her dual appointments reflect an interdisciplinary research program spanning molecular mechanisms of stem cell regulation and neural development. Dr. Brand earned her PhD from the University of Cambridge followed by prestigious postdoctoral fellowships: a Leukemia Society Special Fellowship at Harvard Medical School and a Helen Hay Whitney Fellowship at Harvard University. These foundational experiences established her expertise in genetic model systems. Her research integrates stem cell biology and neuroscience through innovative work with Drosophila and mouse models. Key investigations focus on chromatin dynamics in stem cell quiescence, Notch/insulin signaling pathways, neural progenitor reprogramming, and blood-brain barrier formation. Current projects explore obesity-related gene function and CHD8 genomic targets relevant to neurodevelopmental disorders, emphasizing translational potential for regenerative medicine. Recent publications (2020-2022) reveal consistent themes in stem cell niche organization and disease mechanisms, with notable contributions to understanding tumorigenesis through neural progenitor studies and metabolic influences on barrier development. Her work demonstrates strong interdisciplinary convergence between developmental genetics and systems neuroscience. No scientific awards were documented in the provided profile information. While the profile indicates Professor Brand's leadership as Department Chair, specific details regarding student mentorship, grant funding, or laboratory structure were not included in the available text. Her position suggests active supervision of research teams and potential involvement in major collaborative initiatives.
Maxim Artyomov is an Alumni Endowed Professor and Professor of Pathology and Immunology at Washington University School of Medicine , with affiliations to the Institute of Clinical and Translational Sciences (ICTS), Bursky Center for Human Immunology & Immunotherapy Programs (CHiiPs), and Siteman Cancer Center. His research spans Systems Immunology , Immunometabolism , and Cancer Immunology , focusing on integrating epigenetic, transcriptional, and metabolic regulation in immune cells. 2018 promoted to Associate Professor with Tenure 2017 awarded LEAP Inventor Challenge 2018 Unanue Prize for Innovative Research in Immunology Key research contributions include: Discovery of itaconate's anti-inflammatory role (2016) Metabolic reprogramming in macrophage polarization (2015) TREM2's function in microglial metabolic fitness (2017) Development of CORESH gene signature search engine (2025) His high-throughput omics pipelines enable cross-disciplinary analysis of immune responses in tuberculosis, Alzheimer's, and cancer. Notable collaborations include work with Schreiber's lab on immune checkpoint therapy (2018) and ITMO University on systems biology workshops (2017-2018). Awards and grants include the Unanue Prize (2018), LEAP Inventor Challenge (2017), and R01 grant from NIAID (2017). He mentors PhD/MSTP students and co-organizes international systems biology workshops.
Zhandong Liu is an Associate Professor at Baylor College of Medicine with joint appointments in the Department of Pediatrics and Department of Neurology . He serves as Chief of Computational Sciences at Texas Children's Hospital and co-directs the Quantitative & Computational Biosciences Graduate Program at Baylor. Education: B.S. in Computer Science, Nankai University (2001) M.S. in Computer Science, Wayne State University (2003) Ph.D. in Genomics and Computational Biology, University of Pennsylvania (2010) Dr. Liu's research integrates genomics , machine learning , and bioinformatics to advance understanding of neurological diseases. His work focuses on: Multi-omics data integration for disease mechanism discovery Development of cloud-based CRISPR analysis tools like CRISPRcloud Augmented reality platforms for biomedical data visualization Identification of disease genes through computational models Alternative splicing analysis in cancer and neurodegeneration Single-cell and spatial transcriptomics algorithms His recent publications emphasize Alzheimer's disease , MECP2 syndromes , and computational therapy prediction across multiple domains. Scientific awards include the 2018 Outstanding Service Award from the International Association for Intelligent Biology and Medicine. He has secured major grants from NIH, CPRIT, and NSF for projects including: NSF grant #199977 (2018-2020): Augmented reality therapy platforms CPRIT grant #RP170387 (2016-2019): Network-guided cancer analysis NIH #1R01AG057339 (2017-2022): Alzheimer's disease networks As head of the Liu Lab , he leads teams developing tools like: MARRVEL : Human-model organism gene variant integration CRISPRcloud : Secure CRISPR screen analysis platform CrypSplice : Cryptic splicing detection algorithm
Justin Milner, PhD, serves as Assistant Professor in the Department of Microbiology and Immunology at the University of North Carolina at Chapel Hill School of Medicine and is a member of the UNC Lineberger Comprehensive Cancer Center. His research develops novel approaches to enhance cancer immunotherapies through multi-omics and bioengineering techniques. Education: Postdoctoral Fellowship, UCSD PhD, UNC Chapel-Hill BS, UNC Chapel-Hill Dr. Milner's lab investigates molecular drivers of T cell differentiation and function within tumor microenvironments, utilizing cutting-edge genomics, bioengineering, and computational immunology. His work focuses on reprogramming T cell activity to overcome immunotherapy resistance in cancers, with particular emphasis on epigenetic regulation and metabolic adaptations of tumor-infiltrating lymphocytes. Recent projects explore hydrogel-based delivery systems for immunotherapeutics and transcriptional networks governing T cell exhaustion. Analysis of his 15 most recent publications reveals dominant themes in cancer immunotherapy enhancement, particularly through T cell engineering (7/15 articles), tumor microenvironment modulation (5/15), and computational approaches to T cell biology (3/15). Key methodologies include single-cell multi-omics, in vivo screening, and biomaterial-based drug delivery systems targeting solid tumors. Scientific Awards: NIH NCI K99/R00 Pathway to Independence Award V Foundation Scholar Award Lung Cancer Initiative Career Development Award UNC Lineberger Innovation Award Multiple institutional pilot awards including Hirschberg Foundation and Mary Kay Ash Awards Dr. Milner currently advises three graduate students and multiple postdoctoral researchers while leading an NIH-funded R01 project ($2.79 million) investigating epigenetic regulation of T cell exhaustion. His lab maintains active collaborations across computational medicine and pancreatic cancer research programs at UNC. The Milner Lab operates within the UNC Lineberger Comprehensive Cancer Center, utilizing core facilities for single-cell genomics, murine tumor modeling, and bioengineering. Current team includes seven researchers focused on T cell reprogramming strategies for solid tumor immunotherapy.
Dr. Albert Koulman is a Principal Research Associate at the University of Cambridge, affiliated with the Metabolic Research Laboratories (MRL) within the Institute of Metabolic Science. His work focuses on developing advanced analytical methods for metabolomics and lipidomics to understand metabolic processes in diseases. Department: Department of Clinical Biochemistry, University of Cambridge Key Roles: Scientific Director of the NIHR BRC Metabolomics and Lipidomics facility Research Interests 1. Metabolism in Pregnancy & Early Life: Collaborates with international teams to study lipid metabolism during pregnancy and infancy, developing biomarkers for gestational diabetes, infant nutrition, and childhood obesity risks. 2. Technological Innovations: Leads development of single-cell lipidomics and organelle-specific lipid profiling, establishing a full pipeline from sample preparation to bioinformatics. 3. Nutritional Biomarker Methodology: Specializes in dried blood spot applications for lipid analysis in clinical and population studies, supported by the MRC Epidemiology Unit. Article Trends Recent publications highlight his expertise in lipid metabolism across diseases (e.g., diabetes, melanoma, NAFLD). Key themes include sexual dimorphism in lipid biosynthesis, vitamin D dynamics during exercise, stromal lipid influences on cancer progression, and malnutrition recovery protocols. Methodological advancements (LC-MS/MS, single-cell analysis) and global health applications (Gambian maternal nutrition, pediatric rehabilitation) are recurring topics. Group Members & Collaborations Dr. Ben Jenkins (Analytical Chemist) Ms. Paulina Guevara Dominguez (Research Assistant) Ms. Nina van der Velde (MPhil Student) Collaborators: Sue Ozanne (Pregnancy Metabolism), MJFF (Parkinson’s research), MRC (Epidemiology Unit) Research Funding Biotechnology and Biological Sciences Research Council (BBSRC) JPI (Joint Programming Initiative) Michael J. Fox Foundation (MJFF) Medical Research Council (MRC) National Institute for Health and Care Research (NIHR)
Xiaochen He serves as an Instructor in the Department of Physiology & Biophysics at the University of Mississippi Medical Center's School of Medicine, where he focuses on cardiovascular research and teaching within this foundational medical science department. His research program centers on the intersection of cardiac pathophysiology and immunometabolism, with core interests including: Mechanisms of immune-mediated cardiac inflammation in heart failure Role of T cell subsets (Th17, γδ T, CD8+) in pressure overload models Molecular regulation by IL-12 family cytokines and metabolic enzymes (TIGAR, SIRT3) Endothelial dysfunction in cardiac hypertrophy and failure progression Therapeutic interventions targeting inflammatory pathways Analysis of Dr. He's recent publications (2022-2025) reveals a concentrated research trajectory investigating how specific immune pathways drive heart failure progression. His work consistently employs genetic mouse models to demonstrate that IL-12β inhibition, TIGAR deficiency, and selenium supplementation attenuate cardiac inflammation and dysfunction, while CD8+ T cell metabolic reprogramming exacerbates disease. Key discoveries include GPR174's role in Th17 differentiation and NK1.1 signaling's contribution to cardiopulmonary inflammation, establishing critical immune-metabolic axes in heart failure pathogenesis. No scientific awards were documented in the available profile information. Current departmental records indicate no graduate students are formally listed under Dr. He's mentorship, and no research grants are specified in the public profile. Details regarding laboratory infrastructure, research teams, or collaborative networks were not provided in the available institutional documentation.
Alexander Clarke is an Associate Professor at the University of Oxford's Kennedy Institute of Rheumatology within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, and serves as an Honorary Consultant Rheumatologist at the Nuffield Orthopaedic Centre. His educational background includes medical qualification from UCL in 2001, rheumatology training in London, and a PhD on autophagy in lupus completed in 2013 under Tim Vyse at King's College London. He joined Oxford in 2014 as a postdoctoral fellow with Katja Simon at the Weatherall Institute of Molecular Medicine before establishing his independent research group in 2018. Clarke's research focuses on the intersection of immunology and metabolism, particularly investigating how metabolic pathways regulate immune cell function in autoimmune diseases. His work primarily examines B cell metabolism, autophagy mechanisms, and their roles in conditions like systemic lupus erythematosus. He leads the Clarke Group dedicated to 'Metabolism and Immunity' research. Analysis of his recent publications (2022-2025) reveals a consistent research trajectory centered on immunometabolism, with particular emphasis on germinal center B cells, mitochondrial regulation in lymphocytes, and connections between metabolic pathways and autoimmune pathogenesis. His work bridges fundamental cellular mechanisms with clinical applications in rheumatology. His major scientific recognitions include: Wellcome Trust Clinical Research Training Fellowship Wellcome Trust Clinical Research Career Development Fellowship (2018) Clarke's research program is supported by prestigious Wellcome Trust funding, enabling his group to investigate critical questions at the interface of immunology and metabolism. His work has significant implications for understanding autoimmune disease mechanisms and developing novel therapeutic approaches targeting metabolic pathways in immune cells. The Clarke Group maintains active research programs investigating how metabolic regulation influences immune cell function, with particular focus on B cells in germinal center reactions and their dysregulation in autoimmune conditions.
Dimitrios (Dimitris) Anastasiou is a Senior Group Leader at The Francis Crick Institute in London, UK, specializing in cancer metabolism research. Previously, he served as a Group Leader at the Medical Research Council National Institute for Medical Research (NIMR) starting in 2012 before transitioning to the Crick Institute in 2015. His research career includes postdoctoral work and an Instructor position at Beth Israel Deaconess Medical Center and the Department of Systems Biology, Harvard Medical School under Lewis Cantley, where he focused on metabolic reprogramming in cancer. University College London, UK - BSc Molecular Biology (2001) University of Basel, Basel, Switzerland - PhD in Biochemistry (2006) Anastasiou's research centers on understanding how cancer cells generate energy and utilize nutrients differently from normal cells. His laboratory conducts detailed analyses of metabolic pathways in cancer, investigating how tumor cells rewire their metabolism to support rapid growth and evade the body's defenses. His work spans biochemistry, proteomics, computational systems biology, human physiology, and tumor biology, with particular emphasis on identifying metabolic vulnerabilities that could be targeted for cancer therapy. His innovative approaches include developing chemical 'sensors' to monitor metabolic changes in cancer cells over time as tumors develop. Analysis of his recent publications reveals a consistent focus on metabolic regulation in cancer, particularly regarding glycolysis, hypoxia response, amino acid metabolism, and nucleotide biosynthesis. His work frequently examines enzyme regulation (particularly PKM2), metabolic adaptation to environmental stressors, and the intersection between metabolism and signaling pathways. A notable trend is his exploration of how metabolic enzymes function beyond their traditional roles, influencing cellular signaling and gene expression in cancer contexts. Anastasiou has made significant contributions to understanding metabolic reprogramming in cancer, particularly regarding pyruvate kinase M2 regulation, hypoxia responses, and nutrient utilization in tumor microenvironments. His work bridges basic biochemical mechanisms with potential therapeutic applications, focusing on identifying metabolic vulnerabilities in cancer cells that could be exploited for treatment. As a Senior Group Leader at the Crick Institute, Anastasiou leads a research group investigating how metabolism contributes to disease, particularly cancer. His laboratory utilizes a range of techniques including metabolomics, bioinformatics, structural biology, and high-throughput screening to study metabolic pathways. The group's work aims to identify fundamental differences between metabolic pathways in tumors and healthy tissue to discover new therapeutic targets against cancer.
Tohru Fukai is a Professor and holds the Barbara A. Schnuck Endowed Chair in Translational Medicine at the Medical College of Georgia, Augusta University, where he serves in the Department of Pharmacology and Toxicology. His research is centered at the Vascular Biology Center, where he leads a productive laboratory investigating the molecular mechanisms of oxidative stress and dysfunctional copper metabolism in cardiovascular and metabolic diseases. Dr. Fukai earned his MD in 1988 and PhD in Medical Science in 1995, both from Kyushu University in Japan. Following his medical and doctoral training, he completed postdoctoral fellowship at Emory University School of Medicine in Atlanta from 1995-1999. His research focuses on oxidative stress in cardiovascular and metabolic disease pathogenesis, particularly investigating the role of extracellular SOD (ecSOD, SOD3) and copper transport proteins. His lab has pioneered research on copper transport proteins CTR1, Atox1, and ATP7A in regulating vascular function, demonstrating their critical roles in hypertension, vascular remodeling, inflammatory angiogenesis, atherosclerosis, and diabetes. Notably, his team discovered that copper chaperone Atox1 functions as a copper-dependent transcription factor regulating cell proliferation and inflammatory responses. Analysis of Dr. Fukai's recent publications reveals a strong focus on the intersection of redox signaling, copper metabolism, and vascular function. His work increasingly explores how oxidative stress and copper transport mechanisms contribute to conditions like diabetes, atherosclerosis, Alzheimer's disease, and ischemic injury. A prominent theme across his recent work is the role of protein modifications (particularly sulfenylation and SUMOylation) in regulating vascular responses to oxidative stress, with significant implications for therapeutic interventions. Dr. Fukai's scientific achievements have been recognized with numerous awards including the Barbara A. Schnuck Endowed Chair in Translational Medicine (2017), World Science Leaders in Human Biology Program (2021), and multiple Circulation Research Reviewer Awards. He has served on editorial boards for prestigious journals including Scientific Reports, Journal of Molecular and Cellular Cardiology, and American Journal of Physiology-Heart and Circulatory Physiology. As a mentor, Dr. Fukai has advised numerous graduate students and postdoctoral fellows, including several who have received AHA awards and trainee recognition. He serves on various committees including the VBC post-doc evaluation committee and the CNVAMC Subcommittee for Research Safety. His lab has secured significant funding, including a recent $11.3 million NIH grant for vascular disease research. Dr. Fukai leads an active research group at the Vascular Biology Center comprising senior research associates, assistant research scientists, postdoctoral fellows, and graduate students working collaboratively on multiple projects related to copper transport, redox signaling, and vascular disease mechanisms. His lab has made seminal contributions to understanding how copper transport proteins function as key regulators of vascular antioxidant enzymes and as unexpected signaling molecules in inflammatory disease processes.
G. Petur Nielsen, MD is a Professor of Pathology at Harvard Medical School and serves as Subspecialty Head, Bone and Soft Tissue Pathology at Massachusetts General Hospital . With a clinical focus on bone and soft tissue tumors, his expertise spans diagnostic pathology, molecular genetics of neoplasms, and ancillary testing applications. Research interests center on Pathology and biology of bone/soft tissue tumors Molecular genetics of bone and soft tissue neoplasms Chordoma and sarcoma research Epithelioid vascular tumor differentiation Mesenchymal tumors of the female genital tract His work includes landmark studies on tumor misdiagnosis rates, immunohistochemical profiling, and genomic analysis of chordomas. Scientific contributions appear in leading journals like Nature and American Journal of Surgical Pathology , with major emphasis on Molecular tumor classification Mutational signature analysis Translational oncology Diagnostic accuracy improvement Genomic instability mechanisms
Kathryn E. Dickerson, M.D., M.S.C.S., is an Assistant Professor in the Department of Pediatrics at UT Southwestern Medical Center, specializing in the Division of Hematology and Oncology. She holds dual appointments as a 2015 Translational Research Scholar in the UTSW Center for Translational Medicine and as an NIH KL2 scholar. Her clinical focus is pediatric hematology, emphasizing bone marrow failure disorders, cancer predisposition syndromes, and thalassemia/dyserythropoietic anemias. Her research investigates epigenetic regulation of myeloid malignancies, clonal hematopoiesis in childhood cancer survivors, and molecular mechanisms underlying acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative disorders (MPD). Education: Bachelor's in Biochemistry (Indiana University), minor in Spanish Medical degree (Indiana University School of Medicine) Masters of Science in Clinical Sciences (UT Southwestern Center for Translational Medicine) Training: Pediatric residency with research pathway (Ohio State University/Nationwide Children’s Hospital) Pediatric hematology-oncology fellowship (UT Southwestern) Dr. Dickerson’s research bridges basic science and clinical practice, leveraging CRISPR-based epigenetic editing, genomic analysis, and translational studies to understand disease mechanisms. Key projects include interrogating enhancer dysregulation in leukemia, studying metabolic reprogramming in cancers, and evaluating clonal hematopoiesis in survivors of childhood cancers. Her work has advanced understanding of EZH2’s role in AML and identified therapeutic vulnerabilities in myeloid malignancies. Awards: 2015 Translational Research Scholar (UTSW Center for Translational Medicine) NIH KL2 Career Development Award Grants/Initiatives: NIH-funded investigator-initiated study on clonal hematopoiesis Industry/consortia-sponsored trials for bone marrow failure and rare blood disorders She collaborates with the Children’s Research Institute and North American Pediatric Aplastic Anemia Consortium, contributing to clinical trials and translational initiatives. Her lab focuses on developing biomarkers for disease severity (e.g., immature platelet fraction in pediatric COVID-19) and therapeutic strategies targeting epigenetic dependencies in leukemia.
